Skip to main content

Table 2 ABCD scores at inclusion visit and at each monitoring visit – Quality of life population

From: A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use

  Inclusion visit Monitoring visit 2 months Monitoring visit 12–18 months
  N=197 N=191 N=97
Lipodystrophy score 3.31 (1.14) 2.23 (1.72)* 2.14 (1.61)*
Overall satisfaction with body image 2.56 (0.91) 3.30 (1.03)* 3.13 (1.01)*
Dimension A: Control and adjustment to illness, satisfaction with body image 53.13 (21.24) 67.84 (23.73)* 66.19 (20.04)*
Dimension B: Psychological, social and relational impact 52.13 (22.85) 67.37 (22.84)* 65.08 (18.62)*
Dimension C: Fear of the future 60.00 (24.04) 70.53 (24.08)* 65.08 (18.62)
Dimension D: Impact of treatment 83.74 (21.09) 87.63 (19.74)* 86.60 (19.87)
Overall ABCD quality of life score 56.55 (18.97) 69.93 (20.53)* 67.92 (16.91)*
  1. * Comparison with score at inclusion: Wilcoxon Test, p = <0.001.
  2. † Comparison with score at inclusion: Wilcoxon Test, p = <0.05.
  3. Means provided with standard error of measurement (SEM) in parentheses.
  4. Scores for Dimensions A to D are t-transformed where 0 = worst and 100 = best possible QoL.